Sanofi (SNY) Shares Bought by Concert Wealth Management Inc.
Concert Wealth Management Inc. increased its stake in Sanofi (NYSE:SNY) by 6.5% during the second quarter, Holdings Channel reports. The fund owned 16,532 shares of the company’s stock after buying an additional 1,004 shares during the period. Concert Wealth Management Inc.’s holdings in Sanofi were worth $688,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Sanders Capital LLC raised its position in shares of Sanofi by 4.0% in the second quarter. Sanders Capital LLC now owns 78,297 shares of the company’s stock valued at $3,277,000 after buying an additional 2,997 shares during the last quarter. Prentiss Smith & Co. Inc. raised its position in shares of Sanofi by 16.1% in the second quarter. Prentiss Smith & Co. Inc. now owns 180,111 shares of the company’s stock valued at $7,538,000 after buying an additional 25,027 shares during the last quarter. Grandfield & Dodd LLC bought a new position in shares of Sanofi during the second quarter valued at $3,322,000. Cardinal Capital Management raised its position in shares of Sanofi by 4.1% in the second quarter. Cardinal Capital Management now owns 45,196 shares of the company’s stock valued at $1,891,000 after buying an additional 1,769 shares during the last quarter. Finally, Hamlin Capital Management LLC bought a new position in shares of Sanofi during the second quarter valued at $56,725,000. Institutional investors own 9.42% of the company’s stock.
Sanofi (NYSE:SNY) traded down 0.80% during trading on Tuesday, reaching $38.35. 3,321,252 shares of the company’s stock were exchanged. The stock has a market capitalization of $98.71 billion, a price-to-earnings ratio of 21.41 and a beta of 0.98. The company’s 50 day moving average price is $38.77 and its 200-day moving average price is $40.46. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88.
Several research analysts have weighed in on the stock. Leerink Swann restated a “buy” rating on shares of Sanofi in a research report on Sunday. Piper Jaffray Cos. started coverage on shares of Sanofi in a research report on Friday, September 23rd. They issued a “neutral” rating on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Sanofi in a research report on Thursday, September 15th. Jefferies Group reiterated a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Finally, BNP Paribas upgraded shares of Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. Sanofi presently has an average rating of “Hold” and an average price target of $60.50.
Sanofi Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.